Vitamin D deficiency (VDD), 25-OHD levels <20 ng/ml, is prevalent among patients with sickle cell disease (SCD) and is linked to acute and chronic pain and bone fracture in this population. There is limited literature regarding VDD-associated risk factors for SCD. We examined potential clinical and genomic parameters associated with VDD in 335 adults with SCD in a cross-sectional study. VDD was present in 65% of adult SCD patients, and 25-OHD levels independently and positively correlated with older age (P < 0Á001) and vitamin D supplementation (P < 0Á001). 25-OHD levels were higher in SCD patients over 40 years of age compared to the general African-American population. Both lower 25-OHD levels and increased pain frequency were associated with increased expression of SLC6A5 encoding glycine transporter-2 (GlyT2), a protein involved in neuronal pain pathways. Lower 25-OHD levels were also associated with increased expression of CYP3A4, and with decreased expression of GC (also termed DBP) and VDR, three genes involved in vitamin D metabolism. We conclude that vitamin D supplementation should be an almost universal feature of the care of young adults with SCD, and that further research is warranted into genomic factors that regulate vitamin D metabolism in SCD.
Vitamin D is synthesized from 7-dehydrocholesterol when skin is exposed to ultraviolet light. 7-dehydrocholesterol is hydrolysed first to 25-hydroxyvitamin D (25-OHD) and then to 1,25-dihydroxyvitamin D (1,25-(OH) 2 D), the ligand for the nuclear vitamin D receptor (VDR) (Ramagopalan et al, 2010) . VDR and 1,25-(OH) 2 D form a heterodimer with retinoid X receptor (RXR), which binds vitamin D response elements (VDREs) in genomic sequences and influences gene transcription. Vitamin D is involved in the regulation of multiple biological processes, such as cellular proliferation, differentiation and apoptosis, calcium metabolism and bone health (Arnson et al, 2007; Holick, 2007) . Multiple genes are involved in the vitamin D metabolism pathway (Jolliffe et al, 2016) . Cytochrome P450 2R1 (CYP2R1) and cytochrome P450 27B1 (CYP27B1) encode the most important hydroxylases. Cytochrome P450 24A1 (encoded by CYP24A1) catabolizes both 25-OHD and 1,25-(OH) 2 D. Vitamin D binding protein (encoded by GC, also termed DBP) binds to 25-OHD in plasma, and is hypothesized to serve as a reservoir and prolong the half-life of 25-OHD (Carpenter et al, 2013; Powe et al, 2013) . In the general population, vitamin D deficiency (VDD), defined as a 25-OHD concentration less than 20 ng/ml, is a risk factor for acute/chronic pain syndromes (Shipton & Shipton, 2015) , cardiovascular (Wang et al, 2012a) , autoimmune (Gatenby et al, 2013) and pulmonary (Gupta et al, 2011; Janssens et al, 2013) diseases, and higher mortality as demonstrated in numerous studies (Melamed et al, 2008; Schottker et al, 2013 Schottker et al, , 2014 Signorello et al, 2013; Chowdhury et al, 2014) . Although most of these studies either had relatively small sample sizes or were metaanalysis or secondary analyses of existing cohorts, they imply that VDD may be a risk factor for various complications in patients with chronic diseases.
A systematic review reported that the prevalence of VDD in sickle cell disease (SCD) populations ranges from 56% to 96% (Nolan et al, 2015) . Patients with SCD tend to have dark skin colour, limited sunlight exposure, poor nutrition and a high prevalence of renal dysfunction, which puts them at a higher risk of developing VDD (Forrest & Stuhldreher, 2011) . VDD in SCD patients leads to lower bone density and increased risk of bone fracture (Sadat-Ali et al, 2011; Arlet et al, 2013) , and is also associated with acute vaso-occlusive crisis (VOC) (Osunkwo et al, 2011; Lee et al, 2015) and use of pain medication (Han et al, 2016) although studies have only been small so far. Vitamin D supplementation resulted in fewer pain days in SCD patients in a small pilot trial (Osunkwo et al, 2012) . Little is known about clinical and genomic risk factors for VDD in SCD. In this study, we evaluated clinical and genomic variables associated with VDD in an adult cohort of SCD patients at the University of Illinois at Chicago (UIC).
Methods

Patient population
A cohort of 335 adults (age ≥18 years old) with SCD followed at the UIC hospital was enrolled in a registry between 2010 and 2014. The study was approved by the Institutional Review Board prior to enrolment and all participants gave written informed consent for participation in the registry.
Data collection
Demographic information and laboratory data were collected from the electronic medical record charting system, Cerner PowerChart. Laboratory data, including 25-OHD levels, complete blood counts with differentials, liver function test and complete metabolic panel, were recorded from a steady-state clinic visit closest to the date when the patient consented to the study. A steady-state clinic visit was defined as an office visit at which the patient was not in an acute vaso-occlusive pain episode. For the mortality follow-up, the dates of death were collected from the medical charts, providers, or the Social Security Death Index search. The length of follow-up was measured using the reverse censoring method (Schemper & Smith, 1996) . For subjects who had not been followed up at UIC during the past 6 months when the data collection was conducted and yielded no positive identification in the Social Security Death Index, the last follow-up date was used for the mortality analysis.
Gene expression analysis
RNA samples were isolated from patient peripheral blood mononuclear cells (PBMCs) within 60 days of the vitamin D level measurement. Messenger RNA was purified, labelled and hybridized to Affymetrix Gene 2.0 ST Array (Affymetrix, Santa Clara, CA, USA). Probe sequences were aligned to human genome assembly GRCh37 (https://www.ncbi.nlm. nih.gov/assembly/GCF_000001405.13) to select for probes with unique perfect alignment. Probes that interrogate multiple gene transcripts and that contain single nucleotide polymorphisms (SNPs) with ≥1% minor allele frequency in the SNP database (dbSNP: https://www.ncbi.nlm.nih.gov/SNP) dataset were removed. Probe intensities were log2 transformed, background corrected and quantile normalized. Probe intensity was extracted by the corresponding probe mean across samples. Gene expression level was summarized as mean intensity across probes within gene, using Gencode version 19 (https://www.gencodegenes.org/releases/19.html). Batch effects of RNA labelling and array hybridization were adjusted using an empirical Bayes method (Johnson et al, 2007) . Patients treated with vitamin D supplement and hydroxycarbamide were excluded, and so 68 patients were analysed for 18 551 autosomal genes. Regression analysis for gene expression was performed on natural log-transformed vitamin D levels adjusting for age, gender and Hb genotype. The false discovery rate (FDR) was determined by Benjamini and Hochberg approach (Benjamini & Hochberg, 1995) . Genes that are involved in the vitamin D metabolism (Jolliffe et al, 2016) were presented. Gene enrichment analysis for GO biological processes was performed using the National Institutes of Health (NIH) DAVID (Huang et al, 2009) .
National Health and Nutrition Examination Survey (NHANES) data analysis
The 25-OHD levels from 2003 to 2004 and 2005 to 2006 NHANES laboratory data (https://www.cdc.gov/nchs/nhanes/ index.htm) were pooled. Analyses were restricted to US-born African Americans aged 18-85 years old. One outlier with 25-OHD level >60 ng/ml was removed, resulting in 2050 subjects. The 25-OHD levels between NHANES and UIC cohorts for age categories were compared using a two-tailed Wilcoxon rank sum test. The two-tailed Cruzik's test was used to estimate the trend of 25-OHD levels across age categories of ≤29, 30-39, 40-49 and ≥50 years for both the UIC and NHANES cohorts. To compare the trend difference, a linear regression model was used to test the interaction between disease status (SCD for UIC and normal for NHANES) and age categories (<40 and ≥40 years) on logtransformed 25-OHD levels.
Effects of vitamin D supplementation
Weekly oral ergocalciferol (50 000 units) is often prescribed to patients who had a 25-OHD level less than 20 ng/ml in our institution. Twenty-five of the patients prescribed ergocalciferol had a repeat measurement of 25-OHD levels within 180 days. The Wilcoxon signed-rank test was used to compare 25-OHD levels before and after supplementation.
Statistical analysis
The SCD patients were divided into three groups based on 25-OHD levels: <20 ng/ml (VDD), 20-29 ng/ml (vitamin D insufficiency), or ≥30 ng/ml (vitamin D sufficiency) (Holick, 2007) . The baseline characteristic differences based on 25-OHD levels were compared using the Jonckheere-Terpstra In the multivariable analysis, a stepwise linear regression was used. The backward regression had an entry probability of 0Á2 and an exit probability of 0Á1. The 25-OHD levels were transformed as loge(25-OHD). To measure the seasonal 25-OHD variations, a calendar year was categorized into four quarters (November-January, February-April, May-July and August-October) based on the duration of daylight (Astronomical Applications Dept., U. S. Naval Observatory, Washington, DC; http://aa.usno.navy.mil/data/d ocs/Dur_OneYear.php), and the Kruskal-Wallis test and the Conover-Inman Test for All Pairwise Comparisons were used to compare 25-OHD levels in different quarters. A stepwise Cox proportional hazards regression model was used to analyse the mortality risk. SYSTAT 13 (Systat Software Corporation, Chicago, IL, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA) were used for most analyses. For gene expression analysis, linear regression was applied to model vitamin D level (natural log transformed) using gene expression, age, gender, and SCD Hb genotype as explanatory variables. The significance of gene expression term was estimated using v 2 test with 1 degree of freedom. P-values were adjusted for multiple comparisons using Benjamini and Hochberg method (Benjamini & Hochberg, 1995) .
Results
Clinical correlates of vitamin D deficiency
The 335 SCD adult patients who had 25-OHD levels measured included 252 with Hb SS or S/beta 0 thalassaemia (SS/Sbeta 0 ), 63 with Hb SC and 20 with Hb S/beta + thalassaemia. The median age (interquartile range [IQR] ) was 32 (24-44) years. Thirty-nine percent were male, and 40% were taking hydroxycarbamide therapy at the time of 25-OHD levels measured. The 25-OHD levels were not normally distributed (one-sample Kolmogorov-Smirnov test P < 0Á01), and the median 25-OHD level was 14 (IQR 9-23) ng/ml. The SCD patients were divided into three groups based on 25-OHD levels (<20 (VDD), 20-29, or ≥30 ng/ml). The majority of patients (65%) had VDD, and this proportion increased to 77% of those in the <40 years of age category. The patient characteristics in each group are summarized in Table I . All three groups had similar percentage of male patients and Hb SS/Sbeta 0 patients. The median age was significantly older as 25-OHD levels increased (P < 0Á001), whereas glomerular filtration rate (GFR) was reduced as 25-OHD levels increased (P = 0Á008) due to the confounding effect of age. The groups with higher 25-OHD levels had more patients on vitamin D supplementation at the time the 25-OHD levels were measured (P = 0Á002). White blood cell (WBC) counts were higher in groups with lower 25-OHD levels (Table I) . Multivariable regression analysis identified lower 25-OHD levels as being independently associated with younger age (P < 0Á001) and lack of vitamin D supplementation (P < 0Á001) ( Table II) .
Comparison of 25-OHD levels in the UIC SCD cohort and NHANES African Americans UIC SCD patients in the 40-49 years and ≥50 years old groups had higher levels of 25-OHD than younger age groups (P < 0Á001) (Fig 1) . NHANES data also showed a positive trend between 25-OHD levels and age in the general AfricanAmerican population (P < 0Á001). When the UIC cohort was compared to the NHANES cohort, there was no significant difference in 25-OHD levels for the 18-29 years (P = 0Á31) or 30-39 years (P = 0Á15) age groups, but the levels were higher in the UIC cohort in the 40-49 and ≥50 year age groups (P < 0Á001). Older age was associated with increased 25-OHD levels in both SCD and normal individuals, but the magnitude of 25-OHD level increase with age was greater in SCD than the general African American population (P < 0Á001).
Seasonal 25-OHD variation
Sun exposure leads to the photosynthesis of vitamin D (Holick, 2007) , which may cause seasonal variation in 25-OHD levels. When 25-OHD levels were evaluated based on daylight duration, those in the quarter with the least sun exposure (November-January) were the lowest, which was significantly lower than those measured in the fourth quarter (Table III) , emphasizing the importance of vitamin D supplementation during the months with the least daylight.
Differential gene expression associated with 25-OHD levels
To investigate differential PBMC gene expression associated with 25-OHD levels, a genome-wide association study was conducted after adjusting for age, gender, and sickle cell Hb genotype. A total of 993 genes were positively associated with 25-OHD levels at FDR <0Á05, and 634 genes were negatively associated (Tables SI and SII) . They were enriched for several pathways including Fc gamma R-mediated phagocytosis, inositol phosphate metabolism and olfactory transduction (Table SIII) , but the implication of these pathways in the SCD pathophysiology is unknown. The expression of three genes had the most stringent genome-wide correlation with 25-OHD levels at FDR <0Á01. Expression of Solute Carrier Family 6 Member 5 (SLC6A5) was negatively associated with vitamin D levels (Table SII) . SLC6A5 encodes the glycine transporter-2 (GlyT2), a glycine transporter expressed in neurons that is involved in pain pathways. GlyT2 inhibitors have been investigated as analgesics in various pain conditions (Succar et al, 2007; Hermanns et al, 2008; Morita et al, 2008) . Consistent with its potential function in pain transduction, the gene expression of SLC6A5 was positively correlated with pain frequency (Spearman's r = 0Á16, P = 0Á05, n = 159) in the SCD patients in our cohort. Expression of Minichromosome Maintenance Complex Component 5 (MCM5) and Solute Carrier Family 38 Member 7 (SLC38A7) were positively associated with vitamin D levels. MCM5 is important in cell cycle regulation and is overexpressed in several cancers (Snyder et al, 2005; Wang et al, 2018) . SLC38A7 encodes a glutamine transporter that is important for neuronal physiology and the growth of cancer cells (Verdon et al, 2017) .
A list of 10 key genes involved in vitamin D metabolic and signalling pathways (Jolliffe et al, 2016 ) is presented in Table IV . After adjusting for age, gender and sickle cell Hb genotype, the expression levels of three of these 10 vitamin D metabolic pathway-related genes were associated with serum vitamin D levels at FDR <0Á05. This represents a 3Á4-fold enrichment compared to all analysed genes: 1627 of 18 551 genes (Tables SI and SII) (binomial test P = 0Á05). CYP3A4 expression significantly correlated with lower 25-OHD levels, and GC and VDR expression significantly correlated with higher 25-OHD levels in the genomewide gene expression analysis (Table IV) . CYP3A4 is one of the enzymes that catalyses the hydroxylation of vitamin D, causing clearance of vitamin D (Wang et al, 2013) . DBP (encoded by GC) binds vitamin D in the plasma and prolongs the half-life of 25-OHD (Carpenter et al, 2013; Powe et al, 2013) . VDR forms a complex with 1,25-(OH) 2 D regulating transcriptional responses of downstream targets (Ramagopalan et al, 2010) . Thalassaemia remained in the final regression model. The backward regression had an entry probability of 0Á2 and an exit probability of 0Á1. The 25-OHD levels were transformed as loge(25-OHD). The exponentials of the coefficients and 95% confidence interval (CI) were calculated, and % change was presented. N = 335. The 25-OHD Levels in Different Age Groups. The 25-OHD levels among different age groups were compared using the KruskalWallis test and the Conover-Inman Test for All Pairwise Comparisons. Cruzik's test was used to estimate the trend of 25-OHD levels across age groups of ≤29, 30-39, 40-49, and ≥50 years for both the University of Illinois at Chicago (UIC) cohort and National Health and Nutrition Examination Survey (NHANES) cohort. To test the differential effect of older age (≥40 years) on 25-OHD levels between sickle cell disease patients and normal individuals, log-transformed 25-OHD levels were regressed on age category, disease status and their interaction effect. The boxes denote the inter-quartile range and the whiskers denote the range of the data.
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Vitamin D supplementation
Twenty-five of the patients with VDD were prescribed weekly oral supplementation (50 000 units ergocalciferol) followed by a repeat measurement of 25-OHD levels within 180 days (Fig 2) . The supplementation significantly improved 25-OHD levels (median 10-23 ng/ml, P < 0Á001), and decreased the portion of patients with VDD from 96% (24/25) to 32% (8/25), showing that this supplementation method was an effective approach to increase 25-OHD levels.
Association between 25-OHD levels and mortality in SCD
To examine the impact of VDD on mortality in SCD, the 335 enrolled subjects were followed for a median of 51 months (IQR 31-63 months). Twenty-three patients (6Á9%) died during the follow-up period. Kaplan-Meier analysis of the SCD patients who were divided into three groups based on 25-OHD levels (<20, 20-29, or ≥30 ng/ml) showed a survival benefit of higher 25-OHD levels with a trend towards statistical significance (log-rank P-value 0Á069). When a stepwise Cox proportional hazards regression model was used to analyse the relationship between mortality and 25-OHD levels after adjusting for age, gender, SCD Hb genotype, GFR, WBC count, hydroxycarbamide treatment, and vitamin D supplementation, lower GFR was the only variable significantly associated with higher mortality risk (Hazard ratio [HR] : À0Á01, 95% confidence interval [CI]: Quarters are based on the duration of daylight: 1. November-January; 2. February-April; 3. May-July; 4. August-October. Patients taking vitamin D supplementation when 25-OHD levels were measured were excluded from this analysis. The 25-OHD levels were compared using the KruskalWallis test and the Conover-Inman Test for All Pairwise Comparisons. Table IV . Relationship of serum 25-OHD levels with expression of genes in vitamin D metabolic and signalling pathways.
Gene Gene name Beta P-value Adjusted P-value
The correlation between the expressions of the listed genes involved in vitamin D metabolic pathways and loge(25-OHD) levels was examined after adjusting for age, gender and SCD Hb genotype. , and 25-OHD levels were re-measured within 180 days (median 133 days, interquartile range 114-153 days) after starting supplementation. The Wilcoxon signed-rank test was used to analyse the data (P < 0Á001).
À0Á002 to À0Á019, P = 0Á016). Vitamin D level was not a significant correlate (HR: À0Á292, 95% CI: À0Á879 to 0Á295, P = 0Á329) after adjusting for GFR.
Discussion
Although VDD is common in the general population, it is especially common among African Americans, probably due to difference in skin pigmentation, sun exposure and diet (Forrest & Stuhldreher, 2011) . In our SCD cohort, 65% of the patients (218/335) had VDD. If patients already on vitamin supplementation at baseline are excluded, the prevalence of VDD is 69% (185/268). This is consistent with the published prevalence in SCD patients in a systematic review (Nolan et al, 2015) . In addition to its known role in calcium homeostasis for maintaining skeletal health (Sadat-Ali et al, 2011; Arlet et al, 2013) , vitamin D is important for non-skeleton functions in SCD.
One retrospective study of 53 paediatric patients with SCD showed a correlation between chronic pain and lower 25-OHD levels (Osunkwo et al, 2011) . Another cross-sectional study of 95 paediatric SCD patients associated of lower 25-OHD levels with acute pain (Lee et al, 2015) . Lower 25-OHD levels are also associated with higher opioid usage in SCD patients, as shown in a retrospective study of 203 adult patients (Han et al, 2016) , which seems correctable with high-dose vitamin D supplementation based on a small pilot trial (Osunkwo et al, 2012) . Although most of the studies have been retrospective with small sample sizes, vitamin D levels can be potentially regarded as a health indicator (Chowdhury et al, 2014; Schottker & Brenner, 2015) . An important finding of our study is a strong relationship of SLC6A5 expression with both lower 25-OHD levels and increased pain frequency in the SCD patients in our study. Thus, targeting SLC6A5 and its product, GlyT2, is a potential novel approach to decreasing pain in SCD patients given the role of SLC6A5 in pain pathways (Succar et al, 2007; Hermanns et al, 2008; Morita et al, 2008) . Among key genes involved in vitamin D metabolism (Table IV) , CYP3A4 expression significantly correlated with lower 25-OHD levels in our study and the expression of DBP and VDR correlated with higher levels. CYP3A4 catalyses the hydroxylation of vitamin D leading to metabolic clearance of vitamin D (Wang et al, 2013) . Higher CYP3A4 activity correlates with lower vitamin D levels (Prytula et al, 2016) . Long term treatment with CYP3A4 expression-inducing drugs, such as rifampin, causes drug-induced vitamin D deficiency and osteomalacia (Wang et al, 2012b ). An association between 25-OHD levels and SNPs in CYP3A4 has been observed in a non-African American cohort (Shao et al, 2017) . GC expression correlated with higher vitamin D levels, and DBP seems to serve as a reservoir in the plasma and to prolong the half-life of 25-OHD (Carpenter et al, 2013; Powe et al, 2013) . In a non-SCD African American cohort, two SNPs in GC were found to be significantly associated with 25-OHD levels (Signorello et al, 2011) . In DBP-deficient mice, 25-OHD levels are lower and these mice are more susceptible to VDD manifestations when deprived of vitamin D (Safadi et al, 1999) . VDR expression also correlated with higher 25-OHD levels in our study, which is consistent with previous findings that VDR is positively regulated by 1,25-(OH) 2 D in PBMCs and T cells (Yu et al, 1991; Baeke et al, 2010) .VDR forms a transcription complex with 1,25-(OH) 2 D and RXR that regulates gene transcription of multiple downstream pathways, such as cellular proliferation, calcium metabolism and bone health (Bikle, 2014) .
In this study, patients with VDD have higher WBC counts (Table I) . Vitamin D modulates inflammatory diseases such as infection, asthma and chronic kidney disease (Yin & Agrawal, 2014; Zanetti et al, 2014) . Acute and chronic inflammation contribute to the pathophysiology of SCD and its complications, such as pain crisis and acute chest syndrome (Hoppe, 2014) . Our observation may provide a potential mechanism for how vitamin D may help to decrease chronic and acute pain in SCD (Osunkwo et al, 2011 (Osunkwo et al, , 2012 Lee et al, 2015) and emphasizes the importance of providing vitamin D supplementation to SCD patients with VDD. In our institution, weekly supplementation of oral ergocalciferol is usually prescribed for SCD patients with VDD for 12 weeks, and this has been an effective approach to correct 25-OHD levels (Fig 2) , although some patients need longer duration of treatment or higher dose of supplementation. Weekly high dose oral cholecalciferol supplementation is also effective to restore 25-OHD levels in SCD patients (Osunkwo et al, 2012; Wykes et al, 2014) .
This study is not without limitations. Our study is underpowered to detect a significant association between VDD and mortality. Gene expression was studied in a mixture of PBMCs rather than in purified blood cell fractions. We were unable to replicate our gene expression results in an independent data set. Nevertheless, the enrichment of independently selected vitamin D metabolic pathway genes in the genes associated with 25-OHD levels provides internal verification to our gene expression results. In conclusion, we found evidence that higher 25-OHD levels are associated with older age in adult patients with SCD, and that the differential expression of CYP3A4, GC and VDR may contribute to the difference in 25-OHD levels. Prospective clinical trials with longer follow-up are necessary to evaluate the possible association of VDD with increased SLC6A5 as a mediator of pain and with mortality in SCD, and to precisely characterize the clinical benefits of routine vitamin D supplementation.
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